The administration of ICRE also markedly reduced hepatic steatosis, fasting blood glucose, insulin, and homeostatic model assessment for insulin resistance, serum triglyceride, and total cholesterol levels, suggesting that ICRE can improve HFD-induced fatty liver disease, insulin resistance, and dyslipidemia [45]. The gene discussed is INS; the disease is Insulin resistance.